Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Outcomes for Breast Cancer Survivors Following an Intense Resistance Training Program Based on Surgical Management of the Breast and Axilla.

Annals of surgical oncology·2026
Same author

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

JAMA surgery·2026
Same author

Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.

Future oncology (London, England)·2025
Same author

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

The New England journal of medicine·2025
Same author

Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.

JAMA surgery·2025

Related Experiment Video

Updated: Jul 6, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Neo-adjuvant hormonal therapy.

Marcia Valenzuela1, Thomas B Julian

  • 1Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.

The Breast Journal
|April 1, 2008
PubMed
Summary
This summary is machine-generated.

Neo-adjuvant endocrine therapy, including aromatase inhibitors, offers a less toxic and more effective treatment for locally advanced breast cancer. This approach benefits specific patient groups and improves outcomes, potentially increasing breast-conserving surgery rates.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: Jul 6, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Area of Science:

  • Oncology
  • Endocrinology
  • Breast Cancer Research

Background:

  • Neo-adjuvant endocrine therapy presents new treatment options for locally advanced breast cancer.
  • This therapy is particularly beneficial for elderly patients, those unsuitable for chemotherapy, or those with suboptimal responses.

Purpose of the Study:

  • To evaluate the role and benefits of neo-adjuvant endocrine therapy in locally advanced breast cancer.
  • To identify potential biologic predictors for treatment outcomes.
  • To explore novel agents for adjuvant settings.

Main Methods:

  • Review of current clinical findings on neo-adjuvant endocrine therapies, including aromatase inhibitors.
  • Comparison of efficacy and toxicity profiles against tamoxifen and neo-adjuvant chemotherapy.
  • Analysis of biomarker data (ER, HER-2, PR) for treatment response.

Main Results:

  • Aromatase inhibitors demonstrate superior efficacy and reduced toxicity compared to tamoxifen in the adjuvant setting.
  • Neo-adjuvant endocrine agents are better tolerated and less toxic than neo-adjuvant chemotherapy.
  • Third-generation anti-hormonal therapy shows improved tumor response over tamoxifen, leading to increased breast-conserving surgery rates.

Conclusions:

  • Neo-adjuvant endocrine therapy is a valuable alternative for specific breast cancer patient populations.
  • Biomarker status (ER+, HER-2+, PR+) is crucial for predicting response and guiding future treatment strategies.
  • Further clinical trials are warranted to optimize selective treatment and improve patient outcomes.